JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on TBPH stock, giving a Buy rating on August 13.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Debanjana Chatterjee’s rating is based on the impressive performance and future prospects of Theravance Biopharma’s key products. Yupelri has shown significant growth, with sales exceeding expectations and achieving a milestone due to its approval in China. This success strengthens the belief that future sales could surpass targets, leading to additional financial milestones for the company. Additionally, Trelegy continues to perform well, with sales indicating a strong trajectory that could result in substantial milestone payments for Theravance Biopharma.
Moreover, Ampreloxetine presents a promising opportunity for growth, with its Phase 3 study expected to yield positive results. The potential for this product to address unmet needs in a rare disease market, coupled with the company’s solid financial position and achievable commercial milestones, underscores the potential for significant stock value appreciation. These factors collectively contribute to the Buy rating assigned by Debanjana Chatterjee.
In another report released on August 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.